Astrocyte reactivity influences amyloid- effects on tau pathology in preclinical Alzheimers disease
Furthermore, the option to continue or initiate new AD medication during the trial, including the amyloid lowering monoclonal antibodies, was not a randomization stratification factor and may therefore act as a confounding factor if their use across treatment arms is unequal
Efficacy: Clinical trials have shown both Semaglutide and Tirzepatide to be effective in promoting weight loss
Trial Metric Retatrutide 12mg (TRIUMPH-4) Semaglutide 2.4mg (STEP 1) Mean Weight Loss 28.7% at 68 weeks 14.9% at 68 weeks Mechanism Triple agonist (GLP-1/GIP/GCGR) Single agonist (GLP-1) FDA Status Phase 3 (investigational) Approved (Wegovy) Dosing Weekly subcutaneous Weekly subcutaneous Common Adverse Events GI (nausea, vomiting, diarrhea), dysesthesia GI (nausea, vomiting, diarrhea) Important caveat: These results come from different trial populations and study designs
It works to regulate your blood sugar levels and make you feel full
Always start at the lowest prescribed dose and escalate gradually
